Journal article
Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis
Amy E Taylor, Richard M Martin, Milan S Geybels, Janet L Stanford, Irene Shui, Rosalind Eeles, Doug Easton, Zsofia Kote-Jarai, Ali Amin Al Olama, Sara Benlloch, Kenneth Muir, Graham G Giles, Fredrik Wiklund, Henrik Gronberg, Christopher A Haiman, Johanna Schleutker, Borge G Nordestgaard, Ruth C Travis, David Neal, Nora Pashayan Show all
INTERNATIONAL JOURNAL OF CANCER | WILEY | Published : 2017
DOI: 10.1002/ijc.30462
Abstract
Coffee consumption has been shown in some studies to be associated with lower risk of prostate cancer. However, it is unclear if this association is causal or due to confounding or reverse causality. We conducted a Mendelian randomisation analysis to investigate the causal effects of coffee consumption on prostate cancer risk and progression. We used two genetic variants robustly associated with caffeine intake (rs4410790 and rs2472297) as proxies for coffee consumption in a sample of 46,687 men of European ancestry from 25 studies in the PRACTICAL consortium. Associations between genetic variants and prostate cancer case status, stage and grade were assessed by logistic regression and with ..
View full abstractRelated Projects (1)
Grants
Awarded by Cancer Research UK
Awarded by European Commission
Awarded by National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative (the GAME-ON initiative)
Awarded by European Community's Seventh Framework Programme (iCOGS infrastructure)
Awarded by National Institutes of Health
Awarded by Post-Cancer GWAS initiative
Awarded by Department of Defence
Awarded by Australian NHMRC
Awarded by U.K. Health Technology Assessment (HTA) Programme of the NIH Research (ProtecT study)
Awarded by ProMPT (Prostate Mechanisms of Progression and Treatment)
Awarded by University of Bristol (Integrative Epidemiology Unit)
Awarded by NATIONAL CANCER INSTITUTE
Awarded by Economic and Social Research Council
Awarded by Medical Research Council
Awarded by National Institute for Health Research
Funding Acknowledgements
Grant sponsor: UK Centre for Tobacco and Alcohol Studies, a UKCRC Public Health Research: Centre of Excellence (to A.E.T. and M.R.M.); British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council, and the National Institute for Health Research, under the auspices of the UK Clinical Research Collaboration; Grant sponsor: Cancer Research UK (to R.M.M. and Caroline Relton (Integrative Cancer Epidemiology Programme)); Grant number: C18281/A19169; Grant sponsor: Canadian Institutes of Health Research; (CRUK study and the PRACTICAL consortium); Grant sponsor: European Commission's Seventh Framework Programme; Grant number: 223175 (HEALTH-F2-2009-223175); Grant sponsor: Cancer Research UK; Grant numbers: C5047/A7357, C1287/A10118, C5047/A3354, C5047/A10692, C16913/A6135; Grant sponsor: National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative (the GAME-ON initiative); Grant number: 1 U19 CA 148537-01; Grant sponsor: European Community's Seventh Framework Programme (iCOGS infrastructure); Grant number: 223175 (HEALTH-F2-2009-223175) (iCOGS); Grant sponsor: Cancer Research UK; Grant numbers: C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692; Grant sponsor: National Institutes of Health; Grant number: CA128978; Grant sponsor: Post-Cancer GWAS initiative; Grant numbers: 1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 (GAME-ON initiative); Grant sponsor: Department of Defence; Grant number: W81XWH-10-1-0341; Grant sponsor: Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund; Grant sponsor: VicHealth and Cancer Council Victoria (MCCS cohort recruitment); Grant sponsor: Australian NHMRC; Grant numbers: 209057, 251553 and 504711; Grant sponsor: Victorian Cancer Registry (VCR) and Australian Institute of Health and Welfare (AIHW), including the National Death Index and the Australian Cancer Database; Grant sponsor: U.K. Health Technology Assessment (HTA) Programme of the NIH Research (ProtecT study); Grant numbers: HTA 96/20/99; ISRCTN20141297; Grant sponsor: National Cancer Research Institute (NCRI) formed by the Department of Health, the Medical Research Council and Cancer Research UK [NHS R&D Directorate supported Prodigal study and the ProMPT (Prostate Mechanisms of Progression and Treatment)]; Grant number: G0500966/75466; Grant sponsor: Cancer Research UK (to R.A.E. and Z.K.J.); Grant number: C5047/A7357; Grant sponsor: NIHR Biomedical Research Centre at The Institute of Cancer Research and Royal Marsden NHS Foundation Trust (to RAE and ZKJ); Grant sponsors: National Institute for Health Research Bristol Nutrition Biomedical Research Unit based at University Hospitals Bristol NHS Foundation Trust and the University of Bristol (to R.M.M.); Grant sponsor: NIHR Senior Investigators (to F.C.H., D.E.N. and J.L.D.); Grant sponsors: MRC and the University of Bristol (Integrative Epidemiology Unit); Grant numbers: G0600705, MC_UU_12013/6